5.73
0.00
(0.00%)
At close: January 10 at 8:05:04 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
106,399.00
86,455.00
7,686.00
6,308.00
1,114,200.00
Cost of Revenue
8,775.00
2,159.00
813.00
553.00
565.00
Gross Profit
97,624.00
84,296.00
6,873.00
5,755.00
1,113,635.00
Operating Expense
470,087.00
630,759.00
553,862.00
466,664.00
489,666.00
Operating Income
-372,463.00
-546,463.00
-546,989.00
-460,909.00
623,969.00
Net Non Operating Interest Income Expense
34,744.00
38,743.00
14,190.00
2,883.00
9,597.00
Other Income Expense
125.00
-33,769.00
15.00
134.00
-27,493.00
Pretax Income
-337,594.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
Net Income Common Stockholders
-337,594.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
Diluted NI Available to Com Stockholders
-337,594.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
Basic EPS
-5.57
-9.05
-8.98
-7.80
11.66
Diluted EPS
-5.57
-9.05
-8.98
-7.80
11.43
Basic Average Shares
60,445.93
59,836.44
59,306.09
58,670.23
51,983.19
Diluted Average Shares
60,445.93
59,836.44
59,306.09
58,670.23
53,003.12
Total Operating Income as Reported
-372,250.00
-579,849.00
-546,989.00
-460,909.00
596,226.00
Total Expenses
478,862.00
632,918.00
554,675.00
467,217.00
490,231.00
Net Income from Continuing & Discontinued Operation
-337,594.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
Normalized Income
-337,807.00
-508,103.00
-532,784.00
-457,892.00
633,816.00
Interest Income
34,744.00
38,743.00
14,190.00
2,883.00
9,597.00
Net Interest Income
34,744.00
38,743.00
14,190.00
2,883.00
9,597.00
EBIT
-372,463.00
-546,463.00
-546,989.00
-460,909.00
623,969.00
EBITDA
-371,152.00
-545,070.00
-545,867.00
-456,727.00
626,599.00
Reconciled Cost of Revenue
8,775.00
2,159.00
813.00
553.00
565.00
Reconciled Depreciation
1,311.00
1,393.00
1,122.00
4,182.00
2,630.00
Net Income from Continuing Operation Net Minority Interest
-337,594.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
Total Unusual Items Excluding Goodwill
213.00
-33,386.00
--
--
-27,743.00
Total Unusual Items
213.00
-33,386.00
--
--
-27,743.00
Normalized EBITDA
-371,365.00
-511,684.00
-545,867.00
-456,727.00
654,342.00
12/31/2020 - 12/11/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
6C1.SG CytomX Therapeutics Inc
0.8410
-9.52%
41O.F Outlook Therapeutics, Inc.
2.0600
+0.98%
4A3.F Immatics N.V.
6.84
+1.71%
05Y.F Vivoryon Therapeutics N.V.
2.0200
+1.51%
BVNKF Bavarian Nordic A/S
26.25
0.00%
VVY.AS Vivoryon Therapeutics N.V.
1.9900
-1.49%
POLB.L Poolbeg Pharma PLC
5.15
-8.04%
PHARM.AS Pharming Group N.V.
0.9105
-2.10%